MAPK1/3 regulate hepatic lipid metabolism via ATG7-dependent autophagy.

Yuzhong Xiao,Hao Liu,Junjie Yu,Zilong Zhao,Fei Xiao,Tingting Xia,Chunxia Wang,Kai Li,Jiali Deng,Yajie Guo,Shanghai Chen,Yan Chen,Feifan Guo
DOI: https://doi.org/10.1080/15548627.2015.1135282
IF: 13.391
2016-01-01
Autophagy
Abstract:Although many biological functions of MAPK1/ERK2-MAPK3/ERK1 (mitogen-activated protein kinase 1/3) have been reported, a direct effect of MAPK1/3 on hepatic lipid metabolism remains largely unknown. We recently showed that activation of MAPK1/3 ameliorates liver steatosis in LEPR (leptin receptor)-deficient (db/db) mice, a classic animal model for liver steatosis. Consistent with these results, knockdown of MAPK1/3 promotes liver steatosis in C57/B6J wild-type (WT) mice. Autophagic flux and ATG7 (autophagy related 7) levels are increased by MAPK1/3 activation or decreased by MAPK1/3 knockdown in livers and primary hepatocytes. Blockade of autophagic flux by chloroquine (CQ) or ATG7 knockdown reverses the ameliorated liver steatosis in MAPK1/3-activated db/db mice. Together, these findings identify a beneficial role for MAPK1/3 in liver steatosis that is mediated by ATG7-dependent autophagy, which provides novel insights into the mechanisms underlying liver steatosis and create a rationale for targeting MAPK1/3 in the treatment of liver steatosis.
What problem does this paper attempt to address?